Literature DB >> 1725974

The mucin antigens: what are we measuring?

M R Price1, S Briggs, M J Scanlon, S J Tendler, P E Sibley, C W Hand.   

Abstract

Serum of breast cancer patients contains high molecular weight, mucin-like glycoproteins which are held to be differentiation markers for certain types of normal epithelia, in particular mammary epithelium. These components have primarily been identified using monoclonal antibodies raised against human milk fat globule membranes, tumour extracts or purified mucins. Even so, many of the antibodies produced react with a discrete region of the mucin protein core involving the hydrophilic turn domain APDTRPAP. The present investigation using the anti-urinary mucin antibody, C595, illustrates both the clinical potential of the mucin antigens in breast cancer studies as well as the exquisite specificity of immune recognition of a complex polymorphic glycoprotein at the level of the individual amino acids.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1725974

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  4 in total

1.  Selection of peptide ligands for the antimucin core antibody C595 using phage display technology: definition of candidate epitopes for a cancer vaccine.

Authors:  P Laing; P Tighe; E Kwiatkowski; J Milligan; M Price; H Sewell
Journal:  Clin Mol Pathol       Date:  1995-06

2.  Production and characterization of a recombinant anti-MUC1 scFv reactive with human carcinomas.

Authors:  G Denton; M Sekowski; D I Spencer; O D Hughes; A Murray; H Denley; S J Tendler; M R Price
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  The value of the human milk fat globule membrane antigen HMFG2 in epithelial ovarian cancer monitoring: comparison with CA125.

Authors:  J Fisken; J E Roulston; C Sturgeon; R A Badley; I Jönrup; L Aspinall; R C Leonard
Journal:  Br J Cancer       Date:  1993-05       Impact factor: 7.640

4.  An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells.

Authors:  C Heuser; M Ganser; A Hombach; H Brand; G Denton; F-G Hanisch; H Abken
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.